GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Total Receivables

NovMetaPharma Co (XKRX:229500) Total Receivables : ₩117.89 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Total Receivables?

NovMetaPharma Co's Total Receivables for the quarter that ended in Dec. 2024 was ₩117.89 Mil.


NovMetaPharma Co Total Receivables Historical Data

The historical data trend for NovMetaPharma Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Total Receivables Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.81 82.81 82.05 277.54 117.89

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.81 82.81 82.05 277.54 117.89

NovMetaPharma Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


NovMetaPharma Co Total Receivables Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines